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Background: Levels of Interleukin-6 (IL-6) and C-creative protein (CRP) indicating systemic inflammation are known
to be elevated in chronic diseases including chronic obstructive pulmonary disease (COPD) and depression.
Comorbid depression is common in patients with COPD, but no studies have investigated whether
proinflammatory cytokines mediate the association between pulmonary function and depressive symptoms in
healthy individuals with no known history of obstructive pulmonary diseases.
Methods: In a population-based sample (n = 2077) of individuals aged 55 and above with no known history of
obstructive pulmonary disease in the Singapore Longitudinal Ageing Study (SLAS), we analyzed the relationships
between IL-6 and CRP, depressive symptoms (GDS-15 ≥5) and obstructive pulmonary function (FEV1% predicted
and FEV1/FVC% predicted).
Results: High serum levels of IL-6 and CRP were associated with greater prevalence of depressive symptoms
(p < 0.05). High IL-6, high CRP and depressive symptoms were independently associated with decreased FEV1%
predicted and FEV1/FVC% predicted after adjusting for smoking status, BMI and number of chronic inflammatory
diseases. Increasing grades of combination of inflammatory markers and/or depressive symptoms was associated
with progressive increases in pulmonary obstruction. In hierarchical models, the significant association of depressive
symptoms with pulmonary obstruction was reduced by the presence of IL-6 and CRP.
Conclusions: This study found for the first time an association of depressive symptoms and pulmonary function in
older adults which appeared to be partly mediated by proinflammatory cytokines. Further studies should be
conducted to investigate proinflammatory immune markers and depressive symptoms as potential phenotypic
indicators for chronic obstructive airway disorders in older adults.
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Inverse associationBackground
Although chronic obstructive pulmonary disease (COPD) is
known to be characterized by an intense local inflammatory
response in the lungs, recent research strongly implicates
the role of systemic inflammation as well [1-3]. Raised
levels of the representative pro-inflammatory cytokines,
interleukin (IL)-6 and C-reactive protein (CRP) have
been shown to be associated with low forced expiratory* Correspondence: pcmngtp@nus.edu.sg
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reproduction in any medium, provided the orvolume in one second (FEV1) and FEV1/FVC (forced
vital capacity) indices of chronic pulmonary obstruction in
two population-based studies [4,5], as well as in patients
with stable-state obstructive airway disease [2,6] and during
exacerbation [7]. The presence of systemic inflammation
may explain the known observation that COPD is
frequently found co-morbid with other systemic diseases
such as atherosclerotic disease, diabetes, heart failure,
chronic kidney disease, osteoporosis, sarcopenia, cognitive
impairment and depression which are also characterized
by raised levels of proinflammatory cytokines [1-3].
Depression is a prominent co-morbidity in COPD [8].
Levels of IL-6 and CRP have been shown to be elevated
in individuals with depression [9,10] and decreased afterThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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pathway involving central and systemic responses
underlying the comorbidity of obstructive pulmonary
function and depression is thus possible, but has not been
directly investigated in studies.
In this population-based study of community-living
older adults, we investigated whether proinflammatory
cytokines mediated the association between obstructive
pulmonary function and depressive symptoms in healthy
older adults without a known history of obstructive
pulmonary diseases. We tested the hypotheses that (1)
high serum levels of IL-6 and CRP were associated with
a greater prevalence of depressive symptoms; (2) high
serum IL-6 and CRP levels were associated with FEV1 and
FEV1/FVC measures of obstructive pulmonary function;
(3) depressive symptoms was inversely associated with
FEV1 and FEV1/FVC measures of obstructive pulmonary
function; and (4) the association of depressive symptoms
with FEV1 and FEV1/FVC measures of obstructive
pulmonary function was mediated by IL-6 and CRP.
Methods
Study design and participants
The present study involved selected participants (n = 2077)
in the Singapore Longitudinal Ageing Study (SLAS), a
prospective population-based cohort study of ageing and
health. Details of the study design, sampling procedures
and data collection have been previously described [12].
Briefly, a total population sample (N = 4190) of all older
adults aged 55 years and over, who were residents in
contiguous study localities in South East region (SLAS-1)
and South Central/South West region (SLAS-2) of
Singapore were identified from door-to-door census, and
invited to participate in the study. Residents who were
mentally or physically unable to give informed consent or
participate were excluded. The response rate was 78.5%.
The analytical sample in this study was drawn using
baseline data from the combined SLAS-1 and SLAS-2
cohort members for a total of 2077 study participants
who did not have a known history of asthma or COPD,
who had technically acceptable spirometric measurements
according to American Thoracic Society standards, and for
whom measurements for proinflammatory cytokines were
available from laboratory analyses on serum specimens.
The study was approved by the National University of
Singapore Institutional Review Board. All participants
signed written informed consent for study participation
before completing an extensive range of baseline interviews,
physical examinations and testing.
Depressive symptoms
The presence of depressive symptoms was determined
by the Singapore translation of the 15-item Geriatric
Depression Scale (GDS-15) [13]. The GDS was well suitedfor the study because it is largely free of the measurement
artefact due to overlapping somatic symptoms of physical
illness(es) and depression. Scores range from 0 to 15, and
scores of 5 or more are indicative of depressive symptoms.
In validation studies [13] in the local older population,
translated versions of the GDS-15 have shown high
internal (Cronbach’s alpha 0.80), test-retest (intraclass
coefficient 0.83) and inter-rater reliability (coefficient 0.94).
Pulmonary function
Pulmonary function testing was performed using a portable,
battery operated, ultrasound transit-time based spirometer
(Easy-One; Model 2001 Diagnostic Spirometer, NDD
Medical Technologies, Zurich, Switzerland). Calibration
was checked daily with a 3-L syringe. At least three
acceptable forced expiratory maneuvers were performed
with the respondent seated with recommended guidelines
and standardization of procedures [14]. The measures of
airflow obstruction were (1) forced expiratory volume, 1
sec (FEV1), expressed as a percentage value of predicted
FEV1 based on age, sex, height of the individual (FEV1%
predicted); (2) FEV1/FVC% expressed as a percentage of
the ratio of FEV1 to forced vital capacity (FVC) based on
age, sex, height of the individual (FEV1/FVC% predicted).
Proinflammatory immune markers
Venous blood samples were collected and centrifuged for
10 min at 3,000 r/min at 4°C. The serum was subsequently
removed and stored at -80°C until analysis. Serum con-
centrations of human CRP were determined by a specific
ELISA kit (Chemicon International, Temecula, CA)
according to the manufacturer's instructions. The levels of
serum IL-6 were measured using commercial ELISA kit
(R&D Systems, USA).
Co-variables
Baseline data on co-variables considered to be potential
cofounders included age, height, smoking status, body
mass index, and number of chronic inflammatory diseases
(cardiovascular disease, diabetes, rheumatoid arthritis,
chronic kidney disease, osteoporosis and others).
Statistical analyses
Data analysis was performed using the software package
PASW Statistics version 18 (formerly SPSS, and currently
renamed IBM SPSS). Odds ratio (OR) of association of
high and low levels of IL-6 and CRP with presence of
depressive symptoms were estimated with 95% confidence
intervals (CIs) in chi-squared tests. Levels of IL-6 and
CRP were dichotomized into high and low levels by the
closest approximate median value of each variable.
The association of depressive symptoms, and IL-6 and
CRP levels with pulmonary function was examined in
univariate and multivariable regression analyses. To
Table 1 Socio-demographic status, depressive symptoms,
inflammatory cytokines and pulmonary function of study
participants aged 55 years and over





Age (year, M ± SD) 66.30 ± 7.78
Smoking
Never smoker 1638 78.9
Past smoker 247 11.9
Present smoker 192 9.2
BMI, mean (SD) 23.61 3.68
Chronic inflammatory diseases 1400 67.4
Cardiovascular disease 1279 61.6
Diabetes 318 15.3
Rheumatoid arthritis 254 12.2
Chronic kidney disease 11 0.5
Osteoporosis, and others 67 3.2
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included as covariates smoking status, BMI and number
of chronic inflammatory diseases which are known to
be associated with chronic systemic inflammation and
determined a priori to be important influencing factors
for pulmonary obstruction. To evaluate the role of IL-6
and CRP in explaining the association of depressive
symptoms and pulmonary function, we included IL-6
and CRP in hierarchical models to observe their impact
on depressive symptom– pulmonary function association.
We used ANCOVA (adjusting for smoking status,
BMI and number of chronic inflammatory diseases) to
compare differences in mean FEV1% predicted and FEV1/
FVC% predicted among combination groups with low,
moderate or high levels of inflammation and combination
groups of high inflammation and depressive symptoms:
low GDS-low inflammation, low GDS-high inflammation,
high GDS-low inflammation, high GDS-high inflammation.
Combined low IL-6 and low CRP were considered as
low inflammation; combined high IL-6 or high CRP
were considered as moderate inflammation; combined high
IL-6 and high CRP were considered as high inflammation.No. of chronic inflammatory diseases 1.31 1.22
GDS Score(M ± SD) 1.07 ± 2.02
GDS <5 1964 94.6
GDS≥ 5 113 5.4
C-reactive protein (g/dL)
Mean ± SD 22.95 ± 55.1
Median, inter-quartile values 9.65 4.26, 19.64
Low CRP (≤9.65) 1206 58.1
High CRP (>9.65) 871 41.9Results
Sample characteristics
The average age of the study sample was 66.3 years.
Among the respondents, 36.7% were males, and 63.3%
were females. The proportion of past and current
smokers among respondents was 21.1%. Table 1 shows
the socio-demographic characteristics, mean scores of
pulmonary function, depressive symptoms, and levels of
proinflammatory immune markers in study participants.IL-6 (pg/ml)
Mean ± SD 3.19 ± 6.73
Median, inter-quartile values 2.00 2.00, 2.50
Low IL-6 (≤2.00) 1338 64.4
High IL-6 (>2.00) 739 35.6
FEV1 (litre, years, M ± SD) 1.81 ± 0.56
FEV1 % Predicted (M ± SD) 99.22 ± 23.4
FEV1/FVC% predicted (M ± SD) 86.43 ± 13.3
FEV1% predicted <80%, n (%) 374 18.0Depressive symptoms and proinflammatory markers
A greater prevalence of GDS ≥ 5 depressive symptoms
was found among participants with high levels of serum
IL-6 compared with those with low levels of serum IL-6
(7.1% vs. 4.5%, χ2 = 6.092, OR = 1.61, 95% CI 1.10-2.37,
p = 0.014) and among participants with high levels of
CRP compared to those with low levels of CRP (6.2% vs.
4.3%, χ2 = 3.976, OR = 1.49, 95% CI 1.01-2.20, p = 0.046).
See Table 2.FEV1/FVC% predicted <70.0% 296 14.3Depressive symptoms and pulmonary function
FEV1% predicted and FEV1/FVC% predicted were
significantly lower for respondents with depressive
symptoms, in comparison to respondents without
depressive symptoms, and remained significant in the
regression model that controlled for smoking status,
BMI and number of chronic inflammatory diseases
(Model 1) (Table 3).Proinflammatory markers and pulmonary function
As shown in Table 3, FEV1% predicted and FEV1/FVC%
predicted were significantly lower for respondents with
high levels of serum IL-6 and CRP, in comparison to
respondents with low levels of serum IL-6 and CRP,
and remained significant after adjusting for smoking
status, BMI and number of chronic inflammatory diseases
in Model 1.
Table 2 Prevalence of depressive symptoms (GDS ≥ 5)
by levels of IL-6 and CRP
GDS ≥ 5, n (%) χ2 OR (95% C.I) P
Low IL-6 60 (4.5)
High IL-6 52 (7.1) 6.092 1.61 (1.10-2.37) 0.014
Low CRP 52 (4.3)
High CRP 54 (6.2) 3.976 1.49 (1.01-2.20) 0.046
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As shown in Figure 1, the group with combined high
IL-6-and high CRP was found to have significantly lower
values of FEV1% predicted (Figure 1A) and FEV1/FVC%
predicted (Figure 1B) than the groups with low IL-6-low
CRP (p < 0.001) and high IL-6 or high CRP (p < 0.01).
Combination of inflammation and depressive symptoms
and obstructive pulmonary function
Participants with low GDS-high inflammation had
significantly lower mean FEV1% predicted than those with
low GDS-low inflammation (p < 0.01) (Figure 1C). Signifi-
cantly lower values of FEV1/FVC% predicted were found in
groups of low GDS-high inflammation and high GDS-high
inflammation compared with low GDS-low inflammation
group (p < 0.05).
Mediational analyses
To assess whether proinflammatory immune markers
mediated the association between depressive symptoms
and obstructive pulmonary function, statistical mediation
was tested as recommended by Stone [15]. As shown in
Table 3, the introduction of IL-6 and CRP in Model 2Table 3 Hierarchical regression analyses of association of dep
mediating effect of CRP and IL-6
Independent FEV1 % Predicted
Variables B SE β t
Base model Unadjusted
GDS (versus <5) −4.934 2.331 −0.047 −2.117
CRP (versus low) −4.397 1.096 −0.096 −4.010
IL-6 (versus low) −5.137 1.086 −0.105 −4.730
Model 1 Adjusted for smoking
GDS (versus <5) −4.715 2.340 −0.045 −2.015
CRP (versus low) −4.239 1.131 −0.092 −3.747
IL-6 (versus low) −4.901 1.096 −0.100 −4.471
Model 2 Adjusted for smoking, BMI, No.
GDS (versus <5) −3.895 2.332 −0.040 −1.670
CRP (versus low) −3.506 1.151 −0.076 −3.047
IL-6 (versus low) −3.584 1.164 −0.075 −3.079substantially reduced the level and significance of the
association between depressive symptoms and FEV1%
predicted and FEV1/FVC% predicted, while the association
of IL-6 and CRP with obstructive pulmonary function
remained significant.
Discussion
This population-based study showed firstly an association
between depressive symptoms and obstructive pulmonary
function in apparently healthy older adults with no known
obstructive pulmonary diseases. This is consistent with
results from prior research based on studies of patients
with asthma and COPD which showed markedly increased
prevalence of depression [8,16-18]. Our results are in
agreement with the findings in a population-based study
of US adults [19] which observed that participants with
obstructive pulmonary dysfunction were significantly more
likely to present with depressive symptoms compared with
controls without pulmonary dysfunction.
Secondly, we found a positive association between serum
levels of IL-6 and CRP with depressive symptoms. This
adds to the accumulating evidence from meta-analyses
showing elevated levels of IL-6 and CRP in individuals with
high levels of depressive symptoms [10] and evidence of the
effects of antidepressant treatment in reducing the levels of
inflammatory markers in depressive episodes [20,21].
Thirdly, serum levels of IL-6 and CRP were also found
to be associated with FEV1 and FEV1/FVC measures of
pulmonary obstruction. This is in agreement with the
results obtained in two recent population-based studies,
[4,5] as well as clinical observations of increased IL-6
and CRP levels in clinically stable patients with airway
obstruction compared to healthy smoker controls [22,23].
Furthermore, IL-6 and CRP haplotypes were shown to beressive symptoms with pulmonary function, and
FEV1/FVC % Predicted
P B SE β t P
0.034 −4.268 2.007 −0.048 −2.127 0.034
<0.001 −4.677 1.025 −0.102 −4.564 <0.001
<0.001 −4.049 1.131 −0.079 −3.580 <0.001
, BMI, no. of chronic inflammatory diseases
0.044 −4.234 2.022 −0.048 −2.093 0.036
<0.001 −5.013 1.059 −0.109 −4.732 <0.001
<0.001 −3.949 1.147 −0.077 −3.443 0.001
of chronic inflammatory diseases, GDS, CRP, and IL-6
0.095 −3.760 1.940 −0.044 −1.938 0.053
0.002 −3.017 0.874 −0.082 −3.451 0.001
0.002 −2.708 0.890 −0.071 −3.043 0.002
Figure 1 Adjusted values of FEV1% predicted and FEV1/FVC% predicted by combined IL-6, CRP and depressive symptoms. (A) Adjusted
values of FEV1% predicted by combined IL-6 and CRP levels; (B) Adjusted values of FEV1/FVC% predicted by combined IL-6 and CRP levels; (C)
Adjusted values of FEV1% predicted by combined GDS and inflammation levels; (D) Adjusted values of FEV1/FVC% predicted by combined GDS and
inflammation levels. Adjusted: smoking, BMI, No. of chronic inflammatory diseases. High GDS (> = 5), Low GDS (less than 5); High Inflammation: high
IL-6 and high CRP; Moderate Inflammation: high IL-6 or high CRP; Low Inflammation: low IL-6 and low CRP. Error bar stands for standard error.
Bonferroni was used for post-hoc test. FEV1 = forced expiratory volume in 1 second; FVC = forced vital capacity; IL-6 = interleukin 6; CPR = C-reactive
protein; GDS = Geriatric Depression Scale. *** p < 0.001, * p < 0.05 vs. the Low IL-6 & Low CRP group; ## p < 0.01 vs. the High IL-6 | High CRP group; +++
p < 0.001, + p < 0.05 vs. the Low GDS & Low inflammation group.
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and higher risk of chronic pulmonary obstruction [24].
Our study extends these findings by indicating that a
combination of high IL-6 and high CRP as well as a
combination of high inflammation and depressive symp-
toms were associated with mounting levels of pulmonary
obstruction.
Our mediational analyses indicated a strong association
of depressive symptoms with spirometric measures of
pulmonary obstruction independent of conventional risk
factors, but the significance of this association was
reduced by the addition of IL-6 and CRP into the
hierarchical model. These results are consonant with
the hypothetical role of chronic inflammation as a
shared underlying pathophysiological process in multiple
organ-system diseases and functional disorders. Pro-
inflammatory immune alterations involving central and
systemic responses may be the common underlying
process explaining why patients with asthma and COPD
commonly present with multiple medical co-morbidities
including depression, cardiovascular disorders, diabetes,obesity, chronic kidney disease, arthritis, osteoporosis
and others.
IL-6 and CRP are primary proinflammatory cytokines
which play important regulatory roles in the acute phase
of inflammation. Studies suggest a direct role of IL-6 in
airway obstruction: (1) IL-6 increases the number of CD4
cells, CD8 cells, B cells, neutrophils, and macrophages
in the lung [25-27], consistent with the changes observed
in human COPD pathology [28]; (2) IL-6 overexpression
leads to emphysema-like airspace enlargement, peri-
bronchiolar collections of mononuclear cells, thickening
of airway walls, subepithelial fibrosis, and airway hyper-
responsiveness [29]; (3) intravenous IL-6 injections into
rats lead to respiratory and peripheral skeletal muscle
wasting [30]; and (4) lung injury is attenuated by the
absence of IL-6 after exposing animals to ozone [31]. In
depression, (1) the inflammatory processes including IL-6
stimulate the release of corticotrophin-releasing hormone
(CRH) and heighten hypothalamic-pituitary-adrenal axis
activity, which leads to elevated cortisol levels to initiate
and/or worsen symptoms of depression [32,33]; (2) central
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states [34]; (3) levels of IL-6 decreases in responders
to antidepressant treatment, while it remains high in
nonresponders [35,36]. A distinctive clinical value of CRP
is its sensitivity and ability to reveal early inflammation
when other clinical parameters are equivocal [37]. Hence,
in patients with chronic obstructive pulmonary disease,
elevated CRP levels have been found to be associated
with reduced FEV1, exercise capacity, metabolic and
functional impairment, hospitalization, all-cause and
COPD mortality [38-40].
Inflammatory process from airway or depression-related
inflammation may hence “spill” over into the systemic
circulation, promoting a generalized inflammatory reaction
which may cause harm centrally and peripherally from
prolonged exposure [41,42]. Our study indicates that
higher levels of IL-6 and CRP combine to produce greater
pulmonary obstruction and depressive symptoms. A
higher index of chronic inflammation and depressive
symptoms in combination were also shown to be associated
with greater pulmonary obstruction, even when it was
adjusted for the presence of high BMI and diagnoses of
chronic inflammatory diseases. These results therefore
suggest that measures of pro-inflammatory immune
markers and depressive symptoms could serve as a clinic-
ally useful index in assessing and subtyping individuals for
risks of obstructive pulmonary disorders.
The present study has strengths and limitations. This
population-based study is largely free of clinical selection
bias from over-sampling of severe cases of diseases,
and also controlled for important potential confounding
by age, sex, smoking, body composition and chronic
inflammatory diseases in our analysis. The GDS used to
assess depressive symptoms is a well validated instrument
that is largely free of somatic symptoms of depression that
overlap with somatic symptoms of physical illness(es). We
analyzed pulmonary obstruction as a continuous variable
using spirometric indices, while excluding known cases of
asthma and COPD. On the other hand, the study sample
very likely included a majority of COPD cases that were
undiagnosed clinically. There was a higher proportion of
females (63.3%) in the sample, consistent with the gender
distribution of the elderly population in ageing societies in
which females have longer life expectancy [43]. Gender
disparity among older Singaporean adults is relatively large
and the older population is therefore disproportionately
female [44,45]. The higher proportions of male and
depressed individuals among the non-participants might
bias the results, possibly towards to the null. Spirometric
measurements and laboratory analyses were available for
only about half of the sample, and this may militate
against the generalization of the results. Participants with
technically unacceptable spirometric measures may likely
include disproportionately more individuals with severeobstructive pulmonary function, and depressive symptoms,
as well as possibly higher levels of inflammatory cytokines,
although these data were not available. The cross-sectional
study design also limits direct causal inferences from
the observed associations; future studies should use
longitudinal designs to assess the association of depression
with proinflammatory immune profiles over time: whether
changes in proinflammatory immune factors are associated
with changes in pulmonary functions, and whether
changes in pulmonary function over time are reflected in
changes in depression levels over time.Conclusions
In conclusion, we found that depressive symptoms was
associated with obstructive pulmonary function, and were
also associated with high levels of serum IL-6 and CRP.
These pro-inflammatory immune markers partially medi-
ated the association of depressive symptoms with ob-
structive pulmonary function, and may delineate the
neurobiological links between depressive symptoms and
pulmonary function. Further studies should be conducted
to better understand the role of inflammatory cytokines
and the use of proinflammatory immune markers in
chronic inflammatory airway diseases.Competing interests
The study was supported by a research grant (No. 03/1/21/17/214) from the
Biomedical Research Council, Agency for Science, Technology and Research
(ASTAR). The authors declare that there are no declarations of interest in
relation to the current study. The authors are responsible for the writing
and the content of this article.Authors’ contributions
YL participated in the recruitment of participants, performed the statistical
analysis and drafted the manuscript. LF, LF and MSN participated in the
recruitment of participants and the statistical analysis of this study. KBY
participated in the design of the study and helped to draft the manuscript.
TPN conceived the study, and participated in its design and coordination
and helped to draft, reviewed and revised the manuscript. All authors read
and approved the final manuscript.Acknowledgements
The authors thank the following voluntary welfare organizations for their
support of the Singapore Longitudinal Ageing Studies: Geylang East Home
for the Aged, Presbyterian Community Services, Thye Hua Kwan Moral
Society (Moral Neighbourhood Links), Yuhua Neighbourhood Link,
Henderson Senior Citizens’ Home, NTUC Eldercare Co-op Ltd, Thong Kheng
Seniors Activity Centre (Queenstown Centre) and Redhill Moral Seniors
Activity Centre.
Author details
1Gerontological Research Programme, Yong Loo Lin School of Medicine,
National University of Singapore, NUHS Tower Block, 9th Floor, 1E Kent Ridge
Road, 119228 Singapore, Singapore. 2Department of Psychological Medicine,
National University Hospital System, NUHS Tower Block, 9th Floor, 1E Kent
Ridge Road, 119228 Singapore, Singapore. 3Department of Geriatric
Medicine, Alexandra Hospital, Singapore, Singapore.
Received: 18 February 2013 Accepted: 7 May 2013
Published: 15 May 2013
Lu et al. Respiratory Research 2013, 14:53 Page 7 of 8
http://respiratory-research.com/content/14/1/53References
1. Corsonello A, Antonelli Incalzi R, Pistelli R, Pedone C, Bustacchini S, Lattanzio
F: Comorbidities of chronic obstructive pulmonary disease.
Curr Opin Pulm Med 2011, 17(Suppl 1):S21–S28.
2. Gan WQ, Man SF, Senthilselvan A, Sin DD: Association between chronic
obstructive pulmonary disease and systemic inflammation: a systematic
review and a meta-analysis. Thorax 2004, 59:574–580.
3. Gompertz S, O'Brien C, Bayley DL, Hill SL, Stockley RA: Changes in bronchial
inflammation during acute exacerbations of chronic bronchitis.
Eur Respir J 2001, 17:1112–1119.
4. Chang SS, Vaz Fragoso CA, Van Ness PH, Fried LP, Tinetti ME: Association
between combined interleukin-6 and C-reactive protein levels and
pulmonary function in older women: results from the Women's Health
and Aging Studies I and II. J Am Geriatr Soc 2011, 59:113–119.
5. Mannino DM, Ford ES, Redd SC: Obstructive and restrictive lung disease
and markers of inflammation: data from the Third National Health and
Nutrition Examination. Am J Med 2003, 114:758–762.
6. Schols AM, Buurman WA, Staal van den Brekel AJ, Dentener MA, Wouters
EF: Evidence for a relation between metabolic derangements and
increased levels of inflammatory mediators in a subgroup of patients
with chronic obstructive pulmonary disease. Thorax 1996, 51:819–824.
7. Hurst JR, Donaldson GC, Perera WR, Wilkinson TMA, Bilello JA, Hagan GW, Vessey
RS, Wedzicha JA: Use of plasma biomarkers at exacerbation of chronic
obstructive pulmonary disease. Am J Respir Crit Care Med 2006, 174:867–874.
8. van Ede L, Yzermans CJ, Brouwer HJ: Prevalence of depression in patients
with chronic obstructive pulmonary disease: a systematic review.
Thorax 1999, 54:688–692.
9. Lindqvist D, Janelidze S, Hagell P, Erhardt S, Samuelsson M, Minthon L,
Hansson O, Bjorkqvist M, Traskman-Bendz L, Brundin L: Interleukin-6 is
elevated in the cerebrospinal fluid of suicide attempters and related to
symptom severity. Biol Psychiatry 2009, 66:287–292.
10. Howren MB, Lamkin DM, Suls J: Associations of depression with C-reactive
protein, IL-1, and IL-6: a meta-analysis. Psychosom Med 2009, 71:171–186.
11. Hiles SA, Baker AL, de Malmanche T, Attia J: Interleukin-6, C-reactive
protein and interleukin-10 after antidepressant treatment in
people with depression: a meta-analysis. Psychol Med 2012,
42(10):2015–2026.
12. Niti M, Ng TP, Kua EH, Ho RC, Tan CH: Depression and chronic medical
illnesses in Asian older adults: the role of subjective health and
functional status. Int J Geriatr Psychiatry 2007, 22:1087–1094.
13. Nyunt MS, Fones C, Niti M, Ng TP: Criterion-based validity and reliability
of the Geriatric Depression Screening Scale (GDS-15) in a large
validation sample of community-living Asian older adults. Aging Ment
Health 2009, 13:376–382.
14. Am J Respir Crit Care MedStandardization of Spirometry, 1994 Update.
American Thoracic Society. 1995, 152:1107–1136.
15. Stone AA: Selected methodological concepts: Mediation and
moderation, individual differences, aggregation strategies, and
variability of replicates. In Stress and disease processes, Perspectives
in behavioral medicine. Edited by Schneiderman N, McCabe P,
Baum A. Hillsdale, NJ, England: Lawrence Erlbaum Associates,
Inc; 1992:55–71.
16. Ng TP, Niti M, Fones C, Yap KB, Tan WC: Co-morbid association of
depression and COPD: a population-based study. Respir Med 2009,
103:895–901.
17. Opolski M, Wilson I: Asthma and depression: a pragmatic review of the
literature and recommendations for future research. Clin Pract Epidemiol
Ment Health 2005, 1:18.
18. Ng TP, Chiam PC, Kua EH: Mental disorders and asthma in the elderly: a
population-based study. Int J Geriatr Psychiatry 2007, 22:668–674.
19. Goodwin RD, Chuang S, Simuro N, Davies M, Pine DS: Association between
lung function and mental health problems among adults in the United
States: Findings from the First National Health and Nutrition
Examination Survey. Am J Epidemiol 2007, 165:383–388.
20. Sluzewska A, Sobieska M, Rybakowski JK: Changes in acute-phase proteins
during lithium potentiation of antidepressants in refractory depression.
Neuropsychobiology 1997, 35:123–127.
21. Kubera M, Kenis G, Bosmans E, Zieba A, Dudek D, Nowak G, Maes M:
Plasma levels of interleukin-6, interleukin-10, and interleukin-1 receptor
antagonist in depression: comparison between the acute state and after
remission. Pol J Pharmacol 2000, 52:237–241.22. Garrod R, Marshall J, Barley E, Fredericks S, Hagan G: The relationship
between inflammatory markers and disability in chronic obstructive
pulmonary disease (COPD). Prim Care Respir J 2007, 16:236–240.
23. de Torres JP, Cordoba-Lanus E, Lopez-Aguilar C, Muros de Fuentes M,
Montejo de Garcini A, Aguirre-Jaime A, Celli BR, Casanova C: C-reactive
protein levels and clinically important predictive outcomes in stable
COPD patients. Eur Respir J 2006, 27:902–907.
24. Yanbaeva DG, Dentener MA, Spruit MA, Houwing-Duistermaat JJ, Kotz D,
Passos VL, Wouters EF: IL6 and CRP haplotypes are associated with COPD
risk and systemic inflammation: a case-control study. BMC Med Genet
2009, 10:23.
25. Yoshida M, Sakuma J, Hayashi S, Abe K, Saito I, Harada S, Sakatani M,
Yamamoto S, Matsumoto N, Kaneda Y, Kishimoto T: A Histologically
Distinctive Interstitial Pneumonia Induced by Overexpression of the
Interleukin-6, Transforming Growth-Factor-Beta-1, or Platelet-Derived
Growth-Factor-B Gene. Proc Natl Acad Sci U S A 1995, 92:9570–9574.
26. Hierholzer C, Kalff JC, Omert L, Tsukada K, Loeffert JE, Watkins SC, Billiar TR,
Tweardy DJ: Interleukin-6 production in hemorrhagic shock is
accompanied by neutrophil recruitment and lung injury. Am J Physiol
Lung Cell Mol Physiol 1998, 275:L611–L621.
27. Park CS, Chung SW, Ki SY, Lim GI, Uh ST, Kim YH, Choi DI, Park JS, Lee DW,
Kitaichi M: Increased levels of interleukin-6 are associated with
lymphocytosis in bronchoalveolar lavage fluids of idiopathic nonspecific
interstitial pneumonia. Am J Respir Crit Care Med 2000, 162:1162–1168.
28. Hogg JC, Chu F, Utokaparch S, Woods R, Elliott WM, Buzatu L, Cherniack RM,
Rogers RM, Sciurba FC, Coxson HO, Pare PD: The nature of small-airway
obstruction in chronic obstructive pulmonary disease. N Engl J Med 2004,
350:2645–2653.
29. Kuhn C III, Homer RJ, Zhu Z, Ward N, Flavell RA, Geba GP, Elias JA: Airway
hyperresponsiveness and airway obstruction in transgenic mice.
Morphologic correlates in mice overexpressing interleukin (IL)-11 and
IL-6 in the lung. Am J Respir Cell Mol Biol 2000, 22:289–295.
30. Janssen SPM, Gayan-Ramirez G, Van Den Bergh A, Herijgers P, Maes K,
Verbeken E, Decramer M: Interleukin-6 causes myocardial failure and
skeletal muscle atrophy in rats. Circulation 2005, 111:996–1005.
31. Johnston RA, Schwartzman IN, Flynt L, Shore SA: Role of interleukin-6 in
murine airway responses to ozone. Am J Physiol Lung Cell Mol Physiol
2005, 288:L390–L397.
32. Penninx BW, Kritchevsky SB, Yaffe K, Newman AB, Simonsick EM, Rubin S,
Ferrucci L, Harris T, Pahor M: Inflammatory markers and depressed mood
in older persons: results from the Health, Aging and Body Composition
study. Biol Psychiatry 2003, 54:566–572.
33. Kiecolt-Glaser JK, Glaser R: Depression and immune function: central
pathways to morbidity and mortality. J Psychosom Res 2002, 53:873–876.
34. Konsman JP, Parnet P, Dantzer R: Cytokine-induced sickness behaviour:
mechanisms and implications. Trends Neurosci 2002, 25:154–159.
35. Lanquillon S, Krieg JC, Bening-Abu-Shach U, Vedder H: Cytokine production
and treatment response in major depressive disorder.
Neuropsychopharmacology 2000, 22:370–379.
36. Basterzi AD, Aydemir C, Kisa C, Aksaray S, Tuzer V, Yazici K, Goka E: IL-6
levels decrease with SSRI treatment in patients with major depression.
Hum Psychopharmacol 2005, 20:473–476.
37. Pepys MB: C-reactive protein fifty years on. Lancet 1981, 1:653–657.
38. Broekhuizen R, Wouters EF, Creutzberg EC, Schols AM: Raised CRP levels
mark metabolic and functional impairment in advanced COPD. Thorax
2006, 61:17–22.
39. Man SF, Connett JE, Anthonisen NR, Wise RA, Tashkin DP, Sin DD: C-
reactive protein and mortality in mild to moderate chronic obstructive
pulmonary disease. Thorax 2006, 61:849–853.
40. Shaaban R, Kony S, Driss F, Leynaert B, Soussan D, Pin I, Neukirch F, Zureik
M: Change in C-reactive protein levels and FEV1 decline: a longitudinal
population-based study. Respir Med 2006, 100:2112–2120.
41. Salvi S, Blomberg A, Rudell B, Kelly F, Sandstrom T, Holgate ST, Frew A:
Acute inflammatory responses in the airways and peripheral blood after
short-term exposure to diesel exhaust in healthy human volunteers. Am
J Respir Crit Care Med 1999, 159:702–709.
42. Maes M, Yirmiya R, Noraberg J, Brene S, Hibbeln J, Perini G, Kubera M,
Bob P, Lerer B, Maj M: The inflammatory & neurodegenerative
(I&ND) hypothesis of depression: leads for future research and
new drug developments in depression. Metab Brain Dis 2009,
24:27–53.
Lu et al. Respiratory Research 2013, 14:53 Page 8 of 8
http://respiratory-research.com/content/14/1/5343. Manton KG: A longitudinal study of functional change and mortality in
the United States. J Gerontol 1988, 43:S153–S161.
44. Yong V, Saito Y, Chan A: Gender differences in health and health
expectancies of older adults in Singapore: an examination of diseases,
impairments, and functional disabilities. J Cross Cult Gerontol 2011,
26:189–203.
45. Singapore DoS: Complete life tables 2006–2008 for Singapore resident
population. Singapore; 2009.
doi:10.1186/1465-9921-14-53
Cite this article as: Lu et al.: Systemic inflammation, depression and
obstructive pulmonary function: a population-based study. Respiratory
Research 2013 14:53.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
